Last reviewed · How we verify

RemifentanilMNTX — Competitive Intelligence Brief

RemifentanilMNTX (RemifentanilMNTX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist with peripheral opioid antagonist. Area: Anesthesia/Analgesia.

marketed Opioid agonist with peripheral opioid antagonist Mu-opioid receptor (agonist: remifentanil; peripheral antagonist: methylnaltrexone) Anesthesia/Analgesia Small molecule Live · refreshed every 30 min

Target snapshot

RemifentanilMNTX (RemifentanilMNTX) — Region Örebro County. RemifentanilMNTX is a combination of remifentanil (a potent opioid agonist) and methylnaltrexone (a peripheral mu-opioid receptor antagonist) designed to provide analgesia while reducing opioid-induced side effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RemifentanilMNTX TARGET RemifentanilMNTX Region Örebro County marketed Opioid agonist with peripheral opioid antagonist Mu-opioid receptor (agonist: remifentanil; peripheral antagonist: methylnaltrexone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist with peripheral opioid antagonist class)

  1. Region Örebro County · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RemifentanilMNTX — Competitive Intelligence Brief. https://druglandscape.com/ci/remifentanilmntx. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: